28th Annual Controversies in the Management of the Patient with HIV

Marshall Glesby, MD, PhD is a Professor of Medicine and Population Health Sciences, Director of the Cornell HIV Clinical Trials Unit, Associate Chief of the Division of Infectious Diseases, and Vice Chair for Faculty Development in the Department of Medicine at Weill Cornell Medical College. He is the Regional Clinical Director of the NECA AETC. He is an Assistant Editor of the Journal of Acquired Immune Deficiency Syndromes and a former member of the Antiviral Drugs Advisory Committee of the Food and Drug Administration (FDA). Dr. Glesby has co-authored over 150 peer reviewed articles.

Dr. Gulick is a Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine and Attending Physician at the New York Presbyterian Hospital in New York City.  He is board certified in internal medicine and infectious diseases.

Dr. Gulick’s research interests include designing, conducting, and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiviral agents with new mechanisms of action.  He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. 

He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection.   He previously served as the Co-Chair of the NIH COVID-19 Treatment Guidelines Panel, as a Member and as Chair of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as a Member and as Chair of the NIH Office of AIDS Research Advisory Committee (OARAC).  He is a Member of the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), International AIDS Society (IAS), and the Infectious Diseases Society of America (IDSA) and has presented at national and international meetings and published widely.

Charles W. Flexner, M.D., is a Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.  He is also Professor of International Health at the Bloomberg School of Public Health.  He is Interim Director of the Division of Clinical Pharmacology at Johns Hopkins. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. He has published extensively on antiviral and antibiotic drug transport and metabolism, and metabolic drug interactions. His current research focuses on the discovery and development of new molecules and formulations for long-acting administration for the treatment and prevention of HIV and related infections. He is founder and director of the Long-Acting/Extended-Release Antiretroviral Research Resource Program (LEAP; www.longactinghiv.org), providing advice and support to international stakeholders including the NIH, World Health Organization (WHO), Bill and Melinda Gates Foundation, and Unitaid. He is Co-Director of the Johns Hopkins University Baltimore- India HIV Clinical Trials Unit (JHUBI CTU). Dr. Flexner is Deputy Director of the Graduate Training Programs in Clinical Investigation, and is Chief Scientific Officer of the Institute for Clinical and Translational Research at Johns Hopkins. He serves on the editorial boards of 12 scientific journals. He is a long-standing member, and the only pharmacologist, on the WHO Clinical Guidelines Development Group for Treatment and Prevention of HIV in Adults, Adolescents, and Children.

Teresa H. Evering, M.D., M.S. is an Assistant Professor of Medicine in the Division of Infectious Diseases at Weill Cornell Medicine, which she joined in 2020. She received her M.D. from Weill Cornell, completed residency at NewYork-Presbyterian/Columbia, and trained as an Infectious Disease Fellow at Albert Einstein College of Medicine/Montefiore Medical Center. She earned her M.S. in translational research through the Rockefeller University–sponsored Clinical Scholar’s Program at the Aaron Diamond AIDS Research Center. Dr. Evering’s research focuses on HIV-1 infection of the central nervous system and HIV-associated neurocognitive disorders (HAND), integrating phylogenetic, molecular, and systems biology approaches.

Gregg Gonsalves is an Associate Professor in the Department of the Epidemiology of Microbial Diseases at Yale School of Public Health and an Associate Professor (Adjunct) at Yale Law School. At Yale, he also co-directs the Global Health Justice Partnership, an initiative of YSPH and YLS, working at the intersections of health and human rights and social justice. For close to 35 years, he has been an AIDS activist, working first with the AIDS Coalition to Unleash Power (ACT UP) in Boston and New York, then co-founding the Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC). He has also worked with Gay Men’s Health Crisis in New York and the AIDS and Rights Alliance for Southern Africa in Cape Town. He is a 2018 MacArthur Fellow.

Dr. Grant Ellsworth is an Assistant Professor of Medicine in the Division of Infectious Diseases at WCM.  His primary research interest is the prevention of cancers including HPV-related cancer and Lung Cancer.  He is the AIDS Malignancy Consortium site PI for WCM and is contact PI for National Cancer Institute funded partnership evaluating various HPV-related screening and prevention interventions in persons with HIV in the Americas.

Dr. Magda Sobieszczyk is the Chief of Infectious Diseases at the Columbia University Medical Center in New York. She is a clinical virologist and an infectious disease specialist.

Her research focuses on the development, testing, and implementation of biomedical interventions to prevent HIV infection:  vaccines, monoclonal antibodies, and pre-exposure prophylaxis (PrEP). Her work also extends to testing strategies to promote uptake of new biomedical interventions.

R. Brad Jones, PhD, is an Associate Professor of Immunology in Medicine at Weill Cornell Medicine, where he leads a research program focused on HIV immunopathogenesis and cure strategies. His work integrates virology, immunology, and translational science to develop and test novel approaches for eliminating persistent HIV reservoirs. Dr. Jones serves as multiple principal investigator for large NIH-funded collaboratories, including REACH and INSPIRE, and has pioneered the isolation and study of “authentic reservoir clones” to better understand immune evasion. His research spans basic mechanistic studies to preclinical models, with the goal of informing curative interventions for people living with HIV.